Literature DB >> 25504374

Clinical outcome comparison between TIPS and EBL in patients with cirrhosis and portal vein thrombosis.

Zhu Wang1, He Zhao, Xiaoze Wang, Hailong Zhang, Mingshan Jiang, Jiaywei Tsauo, Xuefeng Luo, Li Yang, Xiao Li.   

Abstract

The aim of this study is to compare the clinical outcomes of transjugular intrahepatic portosystemic shunt (TIPS) and endoscopic band ligation (EBL) in patients with cirrhosis and portal vein thrombosis (PVT). We retrospectively reviewed the January to September 2010 data from our database and included 25 patients with cirrhosis and PVT who underwent successful TIPS creation. We selected another 25 patients who underwent EBL matching for age, sex, and Child-Pugh-Turcotte class. The outcome measures included changes in the PVT status before and after the treatments, the rebleeding rate, and the overall survival. The mean follow-up was 25.1 ± 8.7 months in the EBL group and 25.6 ± 8.5 months in the TIPS group (P = 0.85). After treatments, the PVT severity improved in 40% and worsened in 25% of patients who did not undergo TIPS, compared with 87% and none of the patients who underwent TIPS (P < 0.001). Previous splenectomy (OR 0.13, 95% CI 0.02-0.76, P = 0.024) and patency status of TIPS (OR 20.8, 95% CI 3.0-141.8, P = 0.002) were the independent factors associated with PVT disappearance. The 1- and 2-year rebleeding rates were, respectively, 44.6% and 59.0% in the EBL group, and 12.5% and 25.2% in the TIPS group (P = 0.002). The 1- and 2-year survival rates were, respectively, 95.7% and 85.2% in the EBL group, and 96% and 78.7% in the TIPS group (P = 0.203). The MELD score was the only independent predictive factor for survival (HR 1.73, 95% CI 1.27-2.37, P = 0.001). Compared with EBL, TIPS contributed to PVT improvement and reduced the risk of rebleeding without providing a survival benefit for patients with PVT.

Entities:  

Mesh:

Year:  2015        PMID: 25504374     DOI: 10.1007/s00261-014-0320-9

Source DB:  PubMed          Journal:  Abdom Imaging        ISSN: 0942-8925


  7 in total

Review 1.  Portal vein thrombosis in cirrhosis: Controversies and latest developments.

Authors:  Damian J Harding; M Thamara P R Perera; Frederick Chen; Simon Olliff; Dhiraj Tripathi
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

2.  Percutaneous transhepatic intrahepatic portosystemic shunt for variceal bleeding with chronic portal vein occlusion after splenectomy.

Authors:  Junyang Luo; Mingan Li; Youyong Zhang; Haofan Wang; Mingsheng Huang; Zhengran Li; Junwei Chen; Chun Wu; Jiesheng Qian; Shouhai Guan; Zaibo Jiang
Journal:  Eur Radiol       Date:  2018-03-29       Impact factor: 5.315

Review 3.  Consensus for management of portal vein thrombosis in liver cirrhosis (2020, Shanghai).

Authors: 
Journal:  J Dig Dis       Date:  2021-03-07       Impact factor: 2.325

4.  Transjugular intrahepatic portosystemic shunt for the prevention of rebleeding in patients with cirrhosis and portal vein thrombosis: Systematic review and meta-analysis.

Authors:  Ding-Fan Guo; Lin-Wei Fan; Qi Le; Cai-Bin Huang
Journal:  Front Pharmacol       Date:  2022-08-16       Impact factor: 5.988

5.  Systematic review and meta-analysis of trans-jugular intrahepatic portosystemic shunt for cirrhotic patients with portal vein thrombosis.

Authors:  Jian-Bin Zhang; Jie Chen; Jin Zhou; Xu-Ming Wang; Shu Chen; Jian-Guo Chu; Peng Liu; Zhi-Dong Ye
Journal:  World J Clin Cases       Date:  2021-07-06       Impact factor: 1.337

6.  Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis.

Authors:  Rosa G Simonetti; Giovanni Perricone; Helen L Robbins; Narendra R Battula; Martin O Weickert; Robert Sutton; Saboor Khan
Journal:  Cochrane Database Syst Rev       Date:  2020-10-22

7.  Hemostasis, bleeding and thrombosis in liver disease.

Authors:  Brisas Flores; Hirsh D Trivedi; Simon C Robson; Alan Bonder
Journal:  J Transl Sci       Date:  2017-03-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.